Planning a Pregnancy on GLP-1? Here's the Clinical Timeline

The Current Recommendation

All GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and the newly approved orforglipron — are not recommended during pregnancy or when planning to conceive. Current guidance advises women to stop these medications at least two months before attempting conception, based on pharmacokinetic studies showing the time needed for the drug to fully clear from the body.

For weekly injectable semaglutide and tirzepatide, the two-month washout reflects the drug's half-life (approximately one week for semaglutide, five days for tirzepatide) multiplied by roughly five half-lives for near-complete elimination. Your prescribing provider should help you map this timeline to your conception plans.

What the Safety Data Shows

Animal studies at supratherapeutic doses have shown skeletal abnormalities and fetal growth restriction. However, human data — while still limited — has been more reassuring.

The largest prospective cohort study to date, published by Dao et al. in 2024, examined 168 pregnancies with first-trimester GLP-1 exposure and found no increased risk of congenital anomalies or pregnancy loss. A 2025 Danish nationwide cohort study reached similar conclusions. And a February 2026 study presented at the Society of Maternal-Fetal Medicine meeting found that preconception GLP-1 use was not linked to higher pregnancy risk and may have benefited metabolic health going into pregnancy.

That said, the sample sizes remain small, confidence intervals wide, and no randomized controlled trials have been conducted (nor would they be ethically feasible). The precautionary principle still applies.

Contraception While on GLP-1s

Because GLP-1 medications are not safe during pregnancy, reliable contraception is essential for all women of reproductive age using these drugs. And there's a specific interaction to be aware of:

GLP-1 medications delay gastric emptying, which can reduce the peak concentration and delay the absorption of oral contraceptives. While clinical studies haven't demonstrated a definitive reduction in contraceptive efficacy for most formulations, the interaction is pharmacologically plausible — particularly for progestin-only pills, which have a narrower absorption window.

The semaglutide prescribing information specifically notes that Cmax and AUC of oral contraceptives may be reduced. Some providers recommend switching to non-oral contraceptive methods (IUD, implant, patch, or ring) or adding a barrier method during GLP-1 treatment.

The Preconception Conversation

If you're on a GLP-1 and considering pregnancy in the next 6-12 months, initiate this conversation with both your prescribing provider and your OB/GYN. Key topics to cover include the medication discontinuation timeline based on your specific drug and dose, contraception reliability during the washout period, weight management strategies to minimize rebound gain after stopping the medication, metabolic monitoring during the transition period (A1C, fasting glucose, blood pressure), and whether metformin or other interventions might bridge the gap for patients with insulin resistance or PCOS.

If You Conceive While on a GLP-1

Unplanned pregnancies can and do occur during GLP-1 treatment. Prescribing trends data published in Obstetrics & Gynecology in 2026 showed a rapid rise in perinatal GLP-1 prescriptions — likely reflecting a combination of inadvertent exposure, planned washout periods, and continued first-trimester use.

If you discover you're pregnant while taking a GLP-1 medication, stop the medication immediately and contact your prescribing provider and OB/GYN. Based on current human data, inadvertent early exposure has not been associated with increased rates of major congenital anomalies — but monitoring and specialist consultation are important.

The Bigger Picture

GLP-1 medications and pregnancy planning intersect in a rapidly evolving area of medicine. The evidence is trending toward reassurance for inadvertent early exposure, but the precautionary recommendation to stop two months before attempting conception remains the standard of care. Work closely with your healthcare team to create a timeline that balances metabolic health, weight management, and reproductive safety.